$RGBP.....a great post from the other board:
cvinvestor Wednesday, 03/02/16 04:36:34 PM
Re: the Beek post# 25423
Post # of 25427
We should very well have Orphan Drug Designation within next 2 weeks which should put us more likely above .30.
That followed possibly by funding for the clinical trials once ODD is approved will be interesting.
Q2 is what I'm really waiting for. DCellVax testing data resubmitted (maybe even 2nd FDA approval within Q2 along with new IND for NR2F6.
Can't imagine this trading near current price levels if these 4 things take place.
Remember 2014? Waiting for news for months after they had had discussions with FDA about HemaX and DCellVax and we were left in limbo, only to find out the in house testing didn't meet up with FDA criteria months later? In fact, I truly believe RGBP was spun off in March 2015 in anticipation that it would immediately be followed by both HemaX and dCellVax approval and the price (with only 30M float at that time) would sky rocket. The fact all those tests had to be repeated by GLP labs set us back a good 6 months or more and hundreds of thousands of dollars which caused the heavy dilution later in 2015. That was one tough year and some thought the end of the company - claiming it a scam operation.
Then 2015 gave us outside collaborators, multiple international event presentations, upgrades of abstracts to vocal presentations, GLP labs doing the experiments - 1st IND approval. More patents and SAB members.
Now in 2016, we are collaborating with the NIH / NCATS robotic research against thousands of known and approved compounds in a systemic way. We have a nationally recognized cancer research center and head of a cancer department on board researching NR2F6 as well as overseeing final testing of dCellVax (which gives me confidence that data will meet and be accepted by FDA for 2nd IND approval). Plus we have a new President leading the way for fundraising at higher price points. Plus more new patents.
Yeah, has it taken more time than expected, absolutely. Has it been a long and bumpy road to 2016 - affirmative. But does the future look brighter for RGBP - a hundredfold.
Will RGBP be able to get funds? I think with Lander instead of Koos or Caven at the helm, I think we do, especially when you can say we are working with NIH and John Wayne Cancer Research Center. Yep, I think we can. (Keep in mind that Landers is a scientist and when he talks to investors, he can talk the science and answer questions with credentials to back it up.)
We might have to wait for 2017 for uplisting, but we are no longer waiting for good news for months on end. We have the Lander plan and reason to believe by the end of 2016, we could have 3 approved INDs (HemaX, dCellVax and NR2F6) with possibly another 1, 2, or more in the pipeline: DiffronC, additional molecule inhibitor for NR2F6 and/or expansion of dCellVax for gliomas.
This post is for those of you who are new and haven't been around to see the difference and historical transformation that we've seen over the past couple years. And all of these developments have been positive. Since the setbacks of 2014, I don't recall any setbacks at all in 2015 nor any in 2016. The only reality is needing the cash to push things forward and accomplish what couldn't be done in house. Thus the dilution and my only dilution complaint (which is significant) is that Koos way undervalued and sold us short by issuing shares to friends and family at .025-.05/share which was an insult to us. But Landers knows that and addressed it in his letter that that will no longer be happening under his watch. Let it be so.
cvinvestor Wednesday, 03/02/16 04:36:34 PM
Re: the Beek post# 25423
Post # of 25427
We should very well have Orphan Drug Designation within next 2 weeks which should put us more likely above .30.
That followed possibly by funding for the clinical trials once ODD is approved will be interesting.
Q2 is what I'm really waiting for. DCellVax testing data resubmitted (maybe even 2nd FDA approval within Q2 along with new IND for NR2F6.
Can't imagine this trading near current price levels if these 4 things take place.
Remember 2014? Waiting for news for months after they had had discussions with FDA about HemaX and DCellVax and we were left in limbo, only to find out the in house testing didn't meet up with FDA criteria months later? In fact, I truly believe RGBP was spun off in March 2015 in anticipation that it would immediately be followed by both HemaX and dCellVax approval and the price (with only 30M float at that time) would sky rocket. The fact all those tests had to be repeated by GLP labs set us back a good 6 months or more and hundreds of thousands of dollars which caused the heavy dilution later in 2015. That was one tough year and some thought the end of the company - claiming it a scam operation.
Then 2015 gave us outside collaborators, multiple international event presentations, upgrades of abstracts to vocal presentations, GLP labs doing the experiments - 1st IND approval. More patents and SAB members.
Now in 2016, we are collaborating with the NIH / NCATS robotic research against thousands of known and approved compounds in a systemic way. We have a nationally recognized cancer research center and head of a cancer department on board researching NR2F6 as well as overseeing final testing of dCellVax (which gives me confidence that data will meet and be accepted by FDA for 2nd IND approval). Plus we have a new President leading the way for fundraising at higher price points. Plus more new patents.
Yeah, has it taken more time than expected, absolutely. Has it been a long and bumpy road to 2016 - affirmative. But does the future look brighter for RGBP - a hundredfold.
Will RGBP be able to get funds? I think with Lander instead of Koos or Caven at the helm, I think we do, especially when you can say we are working with NIH and John Wayne Cancer Research Center. Yep, I think we can. (Keep in mind that Landers is a scientist and when he talks to investors, he can talk the science and answer questions with credentials to back it up.)
We might have to wait for 2017 for uplisting, but we are no longer waiting for good news for months on end. We have the Lander plan and reason to believe by the end of 2016, we could have 3 approved INDs (HemaX, dCellVax and NR2F6) with possibly another 1, 2, or more in the pipeline: DiffronC, additional molecule inhibitor for NR2F6 and/or expansion of dCellVax for gliomas.
This post is for those of you who are new and haven't been around to see the difference and historical transformation that we've seen over the past couple years. And all of these developments have been positive. Since the setbacks of 2014, I don't recall any setbacks at all in 2015 nor any in 2016. The only reality is needing the cash to push things forward and accomplish what couldn't be done in house. Thus the dilution and my only dilution complaint (which is significant) is that Koos way undervalued and sold us short by issuing shares to friends and family at .025-.05/share which was an insult to us. But Landers knows that and addressed it in his letter that that will no longer be happening under his watch. Let it be so.
1
